TET2 mutations in other hematologic and non-hematologic malignancies. Somatic alterations in TET2, including deletions and missense, nonsense and frameshift mutations, have been identified in 10–26% of MPN patients [202,203]. This evidence concerns the gene TET2 and myeloproliferative disorder.